Patients with myelofibrosis (MF) may experience different manifestations of disease, including1:

Icon: low hemoglobin levels


Low hemoglobin levels2

Icon: enlarged spleen


An enlarged spleen resulting from extramedullary hematopoiesis1

Icon: symptoms

Constitutional symptoms

Including fatigue, fever, night sweats, pruritus, and weight loss1,2

Icon: low platelet levels


Low platelet levels1,2

Graph icon

Certain manifestations of MF like anemia, constitutional symptoms, and thrombocytopenia are adverse prognostic factors3-5

Percent of MF patients with anemia icon

Within 1 year of diagnosis, ~60% of MF patients are anemic and ~45% are transfusion-requiring6*

Anemic, defined as hemoglobin <10 g/dL. Transfusion-requiring, defined as needing red blood cell (RBC) transfusions.

*A retrospective study based on 1000 consecutive patients with primary MF at time of referral to Mayo Clinic, seen between November 4, 1977, and September 1, 2011. Separate analyses were included for patients seen at time of referral (N=1000), at initial diagnosis (n=340), within 1 year of diagnosis (n=274), and after 1 year of diagnosis (n=386).

Icon: clipboard

While healthcare providers have different tools to treat MF, they may need an FDA-approved MF treatment option for adults with anemia7

See how OJJAARA performed

OJJAARA was assessed in 2 Phase 3 clinical trials in patients who have MF with anemia.

Safety profile icon blue

Explore the safety profile of OJJAARA


Support icon

Find access and support information



  1. Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7:89-101. doi:10.2147/IJGM.S51800
  2. Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(5):801-821. doi:10.1002/ajh.26857
  3. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708. doi:10.1182/blood-2009-09-245837
  4. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901. doi:10.1182/blood-2008-07-170449
  5. Gangat N, Caramazza D, Vaidya R, et al. DIPSS Plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397. doi:10.1200/JCO.2010.32.2446
  6. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc. 2012;87(1):25-33. doi:10.1016/j.mayocp.2011.11.001
  7. Chifotides HT, Bose P, Verstovsek S. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022;15(1):7. doi:10.1186/s13045-021-01157-4